Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument



Status:Terminated
Conditions:High Blood Pressure (Hypertension), High Blood Pressure (Hypertension)
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - 80
Updated:8/24/2018
Start Date:September 1, 2013
End Date:November 30, 2017

Use our guide to learn which trials are right for you!

AC-055-402: An Extension of AC-055-401, a Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument

SYMPHONY Extension is an extension of AC-055-401, a multi-center, open-label, single-arm,
Phase 3b study of macitentan in patients with Pulmonary Arterial Hypertension to
psychometrically validate the PAH-SYMPACT instrument. The objective is to assess the
long-term safety of macitentan in subjects with PAH beyond the treatment in the AC-055-401
study.


Inclusion Criteria:

- Signed informed consent prior to any study-mandated procedure.

- Patients with PAH who completed study AC-055-401

- Women of childbearing potential must:

- Have a negative urine pregnancy test at Visit 1 and agree to perform monthly serum
pregnancy tests.

- Agree to use two methods of contraception from Visit 1 until 1 month after study drug
discontinuation.

Exclusion Criteria:

- Patients who prematurely discontinued study drug in study AC-055-401

- Females who are lactating or pregnant (positive Visit 1 pregnancy test) or plan to
become pregnant during the study

- Known hypersensitivity to macitentan or its excipients or drugs of the same class
We found this trial at
2
sites
Louisville, Kentucky 40202
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials